VKTX
NASDAQViking Therapeutics Inc.
Price$25.17-1.80 (-6.69%)
01:30 PM07:45 PM
News · 26 weeks47+1500%
2026-04-192026-10-11
Mix3090d
- SEC Filings11(37%)
- Other7(23%)
- Insider5(17%)
- Earnings3(10%)
- Offering3(10%)
- Leadership1(3%)
Latest news
25 items- ANALYSTUBS initiated coverage on Viking Therapeutics with a new price targetUBS initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $94.00
- PRViking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with ObesitySUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.The SUNRISE
- PRViking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with ObesityStudy to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735Monthly and Every-Other-Week Subcutaneous Regimens to also be EvaluatedSAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory oral maintenance dosing study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potentia
- SECViking Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
- PRViking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior NotesGross Proceeds to Viking Approximately $575 MillionSAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its concurrent upsized public offerings of 9,035,714 shares of common stock, at a public offering price of $35.00 per share, and $258.75 million aggregate principal amount of 2.00% convertible senior notes due 2032 (the "notes"), which included the full exercise by the underwriters of the common stock offering of their option to purchase an additional 1,178,571 shares of common stock, and the full exerci
- SECSEC Form 424B5 filed by Viking Therapeutics Inc.424B5 - Viking Therapeutics, Inc. (0001607678) (Filer)
- SECSEC Form 424B5 filed by Viking Therapeutics Inc.424B5 - Viking Therapeutics, Inc. (0001607678) (Filer)
- PRViking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior NotesSAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent public offerings of 7,857,143 shares of common stock, at a public offering price of $35.00 per share, and $225.0 million aggregate principal amount of 2.00% convertible senior notes due 2032 (the "notes"). The offering size of each of the common stock offering and note offering was increased from the previously announced offering size of $200.0 million of shares of common stock and $200.0 million aggregate principal amount of notes. The is
- SECSEC Form FWP filed by Viking Therapeutics Inc.FWP - Viking Therapeutics, Inc. (0001607678) (Subject)
- SECSEC Form 305B2 filed by Viking Therapeutics Inc.305B2 - Viking Therapeutics, Inc. (0001607678) (Filer)
- SECSEC Form 424B5 filed by Viking Therapeutics Inc.424B5 - Viking Therapeutics, Inc. (0001607678) (Filer)
- SECSEC Form 424B5 filed by Viking Therapeutics Inc.424B5 - Viking Therapeutics, Inc. (0001607678) (Filer)
- PRViking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior NotesSAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to market and other conditions, $200.0 million of common stock and $200.0 million aggregate principal amount of convertible senior notes due 2032 (the "notes") in separate public offerings registered under the Securities Act of 1933, as amended. Viking also expects to grant the underwriters of the common stock offering a 30-day option to purchase up to an additional $30.0 million of common stock, and expects to grant the underwriters of
- PRToday’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical MineralsDENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The spotlight is heating up across four very different high-catalyst stories: Viking Therapeutics (NASDAQ:VKTX) is pushing its VK2735 obesity program toward Phase 3 while exploring less-frequent maintenance dosing; NeOnc Technologies Holdings (NASDAQ:NTHI) is advancing its NEO100 brain-cancer program after encouraging Phase 2a results; Decoy Therapeutics (NASDAQ:DCOY) is expanding its antiviral platform into high-consequence viruses including Ebola; and Greenland Mines Ltd. (NASDAQ:GRML) is seeking to more than double its exploration footprint at the Sarfartoq rare-earth district. Viking Therapeutics The obesity-drug race
- SECViking Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
- PRViking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens22% Placebo-Adjusted Weight Loss Reported at Week 33 Following Weekly Dosing of VK2735 at 17.5 mg; No Plateau ObservedResults Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to TreatmentUp to 97% of Weight Loss Maintained Following Transition to Every Other Week Dosing for Three Months Up to 90% of Weight Loss Maintained Following Transition to Monthly Dosing for Three MonthsExcellent Tolerability Observed During Maintenance Dosing with GI Adverse Event Rates Similar to PlaceboConference Call Scheduled for 8:00 a.m. ET TodaySAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ
- PRViking Therapeutics to Participate at Upcoming Investor ConferencesSAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Annual Cantor Global Health Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum in September. Details of the company's participation are as follows:2026 Cantor Global Healthcare ConferenceDetails: Viking management will participate in a fireside chat and investor meetings.Conference Dates: Septembe
- INSIDERDirector Kelly-Gemmell Dorothy Elizabeth was granted 6,333 shares (SEC Form 4)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kelly-Gemmell Dorothy Elizabeth3 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- SECSEC Form S-3ASR filed by Viking Therapeutics Inc.S-3ASR - Viking Therapeutics, Inc. (0001607678) (Filer)
- INSIDERPresident & CEO Lian Brian sold $4,947,888 worth of shares (148,517 units at $33.32) and was granted 221,667 shares, increasing direct ownership by 3% to 2,572,441 units (SEC Form 4) to satisfy tax liability4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERChief Financial Officer Zante Greg was granted 31,667 shares and sold $710,141 worth of shares (21,217 units at $33.47), increasing direct ownership by 5% to 212,204 units (SEC Form 4) (for tax liability)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERChief Operating Officer Mancini Marianna was granted 31,667 shares and sold $609,636 worth of shares (18,217 units at $33.47), increasing direct ownership by 3% to 422,760 units (SEC Form 4) (for withholding tax)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- SECSEC Form 10-Q filed by Viking Therapeutics Inc.10-Q - Viking Therapeutics, Inc. (0001607678) (Filer)
- SECViking Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
VKTX FAQ
7 questionsWhat does Viking Therapeutics Inc. do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of...Where does VKTX stock trade?
Viking Therapeutics Inc. (VKTX) is listed on NASDAQ.What sector and industry is VKTX in?
Viking Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Viking Therapeutics Inc. go public?
Viking Therapeutics Inc. (VKTX) completed its IPO in 2015.What are analysts saying about VKTX?
Viking Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-10-15. Recent price targets cluster around $3000.00.What companies are similar to VKTX?
Notable peers in the same industry include LGND (Ligand Pharmaceuticals Incorporated), JNCE (Jounce Therapeutics Inc.), CBAY (CymaBay Therapeutics Inc.), ALRN (Aileron Therapeutics Inc.). Compare VKTX side-by-side with any of them on Quantisnow.How can I track VKTX on Quantisnow?
Quantisnow aggregates Viking Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VKTX to receive live email and push alerts on every new disclosure.